Aprea Therapeutics (NASDAQ:APRE – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.20, Zacks reports. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%.
Aprea Therapeutics Stock Performance
Shares of Aprea Therapeutics stock traded down $0.02 during midday trading on Tuesday, hitting $2.24. 6,539 shares of the company traded hands, compared to its average volume of 18,695. The firm’s fifty day moving average price is $3.15 and its 200-day moving average price is $3.26. The stock has a market cap of $12.17 million, a price-to-earnings ratio of -0.80 and a beta of 0.82. Aprea Therapeutics has a 12 month low of $2.15 and a 12 month high of $6.80.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a report on Wednesday, January 15th.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
Further Reading
- Five stocks we like better than Aprea Therapeutics
- Most Volatile Stocks, What Investors Need to Know
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
- 3 Best Fintech Stocks for a Portfolio Boost
- Oklo’s Stock Price Meltdown Is an Opportunity to Buy
- What is diluted earnings per share (Diluted EPS)?
- Top 3 Insider Stock Buys in March—Are They Still Good in April?
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
